We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+38.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$680B
AUM Growth
+$89.5B
Cap. Flow
-$28.8B
Cap. Flow %
-4.24%
Top 10 Hldgs %
21.1%
Holding
2,615
New
56
Increased
1,632
Reduced
714
Closed
86

Sector Composition

Rank Sector Weight
1 Technology 19.47%
2 Healthcare 18.48%
3 Consumer Discretionary 13.66%
4 Financials 13.47%
5 Communication Services 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HII icon
1026
Huntington Ingalls Industries
HII
$12.8B
$31.4M ﹤0.01%
151,519
+8,325
+6% +$1.71M
CULP icon
1027
Culp Inc
CULP
$43.8M
$31.2M ﹤0.01%
1,623,599
+128,430
+9% +$2.39M
CBRE icon
1028
CBRE Group
CBRE
$42.7B
$31.2M ﹤0.01%
630,494
+40,540
+7% +$1.9M
EIG icon
1029
Employers Holdings
EIG
$864M
$31.1M ﹤0.01%
775,339
-44,675
-5% -$1.89M
PRNB
1030
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$31.1M ﹤0.01%
913,982
+2,010
+0.2% +$63.9K
ALLK
1031
DELISTED
Allakos
ALLK
$31M ﹤0.01%
766,485
+67,127
+10% +$2.71M
AVLR
1032
DELISTED
Avalara, Inc.
AVLR
$31M ﹤0.01%
555,410
-67,905
-11% -$3.15M
BOLD
1033
DELISTED
Audentes Therapeutics, Inc
BOLD
$30.9M ﹤0.01%
790,868
-100,313
-11% -$2.88M
NTAP icon
1034
NetApp
NTAP
$40.2B
$30.8M ﹤0.01%
444,893
+8,600
+2% +$555K
BCS icon
1035
Barclays
BCS
$94.4B
$30.8M ﹤0.01%
3,929,219
-112,640
-3% -$905K
RNR icon
1036
RenaissanceRe
RNR
$13.2B
$30.6M ﹤0.01%
213,203
-11,594
-5% -$1.62M
JAZZ icon
1037
Jazz Pharmaceuticals
JAZZ
$16B
$30.5M ﹤0.01%
213,303
+11,741
+6% +$1.53M
PBYI icon
1038
Puma Biotechnology
PBYI
$450M
$30.5M ﹤0.01%
+785,965
New +$24M
LEN icon
1039
Lennar Class A
LEN
$21.1B
$30.5M ﹤0.01%
641,537
-310,784
-33% -$14.1M
RWT
1040
Redwood Trust
RWT
$592M
$30.3M ﹤0.01%
1,879,133
+1,245
+0.1% +$19.7K
BBY icon
1041
Best Buy
BBY
$18B
$30.2M ﹤0.01%
424,313
CATM
1042
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
$30M ﹤0.01%
843,081
+463
+0.1% +$13.8K
SPOT icon
1043
Spotify
SPOT
$102B
$29.8M ﹤0.01%
214,881
+169,732
+376% +$23.2M
ANET icon
1044
Arista Networks
ANET
$257B
$29.8M ﹤0.01%
1,516,592
+55,200
+4% +$876K
IRWD icon
1045
Ironwood Pharmaceuticals
IRWD
$674M
$29.8M ﹤0.01%
2,629,045
-1,061,830
-29% -$11.9M
CRUS icon
1046
Cirrus Logic
CRUS
$6.11B
$29.8M ﹤0.01%
707,630
-210,191
-23% -$8.11M
GHDX
1047
DELISTED
Genomic Health, Inc.
GHDX
$29.6M ﹤0.01%
423,254
+550
+0.1% +$40.8K
LDL
1048
DELISTED
Lydall, Inc.
LDL
$29.6M ﹤0.01%
1,261,276
-176,987
-12% -$4.48M
GPC icon
1049
Genuine Parts
GPC
$18.5B
$29.5M ﹤0.01%
263,629
+5,610
+2% +$580K
TSS
1050
DELISTED
Total System Services, Inc.
TSS
$29.5M ﹤0.01%
310,706
+6,774
+2% +$612K

Similar funds

T. Rowe Price Associates's Q1 2019 Portfolio in Review

As of Q1 2019, T. Rowe Price Associates held 2,615 positions worth $680B, up 15% from $591B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

T. Rowe Price Associates withdrew a net $28.8B in Q1 2019, closing 86 positions and reducing 714 holdings. Its most notable exit was Twenty-First Century Fox, Inc. Class B, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, T. Rowe Price Associates opened a new position in Fox Class B worth $420M.

  • T. Rowe Price Associates's largest Q1 2019 buy was Fox Class B: 11,707,204 shares worth $420M.
  • T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q1 2019, an estimated $2.84B increase.
  • T. Rowe Price Associates's biggest Q1 2019 reduction was TotalEnergies, cutting an estimated $25.3B.
  • T. Rowe Price Associates fully exited Twenty-First Century Fox, Inc. Class B in Q1 2019, selling an estimated $1.55B.
  • T. Rowe Price Associates's ten largest holdings make up 21% of its $680B portfolio in Q1 2019.
  • T. Rowe Price Associates opened 56 new positions and closed 86 in Q1 2019.
  • T. Rowe Price Associates's portfolio value rose 15% quarter-over-quarter to $680B.

Based on T. Rowe Price Associates's 13F filing for Q1 2019, filed 15 May 2019.